Enoxaparin, a key anticoagulant, helps prevent and treat blood clots

Venus Remedies has received marketing authorisation from Indonesia, Southeast Asia’s largest pharmaceutical market, for its Enoxaparin in pre-filled syringes across all major strengths.

“Indonesia has the highest burden of cardiovascular diseases in the region, driven by an ageing population and lifestyle changes. Our Enoxaparin will offer a cost-effective solution to manage clot-related conditions,” said Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre.

Enoxaparin, a key anticoagulant, helps prevent and treat blood clots, reducing the risk of deep vein thrombosis and pulmonary embolism.